A Colorimetric Test to Differentiate Patients Infected with Influenza from COVID-19

A Colorimetric Test to Differentiate Patients Infected with Influenza from COVID-19. Kozlowski, H. N., Abdou Mohamed, M. A., Kim, J., Bell, N. G., Zagorovsky, K., Mubareka, S., & Chan, W. C. W. Small Structures, 2(8):2100034, 2021. _eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/sstr.202100034

Paper

A Colorimetric Test to Differentiate Patients Infected with Influenza from COVID-19 [pdf]

Paper doi abstract bibtex 1 download

Patients infected with SARS-CoV-2 and influenza display similar symptoms, but treatment requirements are different. Clinicians need to accurately distinguish SARS-CoV-2 from influenza to provide appropriate treatment. Here, the authors develope a color-based technique to differentiate between patients infected with SARS-CoV-2 and influenza A using a nucleic acid enzyme-gold nanoparticle (GNP) molecular test requiring minimal equipment. The MNAzyme and GNP probes are designed to be robust to viral mutations. Conserved regions of the viral genomes are targeted, and two MNAzymes are created for each virus. The ability of the system to distinguish between SARS-CoV-2 and influenza A using 79 patient samples is tested. When detecting SARS-CoV-2 positive patients, the clinical sensitivity is 90%, and the specificity is 100%. When detecting influenza A, the clinical sensitivity and specificity are 93% and 100%, respectively. The high clinical performance of the MNAzyme-GNP assay shows that it can be used to help clinicians choose effective treatments.

@article{kozlowski_colorimetric_2021,
	title = {A {Colorimetric} {Test} to {Differentiate} {Patients} {Infected} with {Influenza} from {COVID}-19},
	volume = {2},
	issn = {2688-4062},
	url = {https://onlinelibrary.wiley.com/doi/abs/10.1002/sstr.202100034},
	doi = {10.1002/sstr.202100034},
	abstract = {Patients infected with SARS-CoV-2 and influenza display similar symptoms, but treatment requirements are different. Clinicians need to accurately distinguish SARS-CoV-2 from influenza to provide appropriate treatment. Here, the authors develope a color-based technique to differentiate between patients infected with SARS-CoV-2 and influenza A using a nucleic acid enzyme-gold nanoparticle (GNP) molecular test requiring minimal equipment. The MNAzyme and GNP probes are designed to be robust to viral mutations. Conserved regions of the viral genomes are targeted, and two MNAzymes are created for each virus. The ability of the system to distinguish between SARS-CoV-2 and influenza A using 79 patient samples is tested. When detecting SARS-CoV-2 positive patients, the clinical sensitivity is 90\%, and the specificity is 100\%. When detecting influenza A, the clinical sensitivity and specificity are 93\% and 100\%, respectively. The high clinical performance of the MNAzyme-GNP assay shows that it can be used to help clinicians choose effective treatments.},
	language = {en},
	number = {8},
	urldate = {2021-11-06},
	journal = {Small Structures},
	author = {Kozlowski, Hannah N. and Abdou Mohamed, Mohamed A. and Kim, Jisung and Bell, Natalie G. and Zagorovsky, Kyryl and Mubareka, Samira and Chan, Warren C. W.},
	year = {2021},
	note = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/sstr.202100034},
	keywords = {colorimetric, diagnostics, DNAzymes, gold nanoparticles, influenza A, respiratory infections, SARS-CoV-2},
	pages = {2100034},
	file = {Full Text PDF:files/1780/Kozlowski et al. - 2021 - A Colorimetric Test to Differentiate Patients Infe.pdf:application/pdf;Snapshot:files/1781/sstr.html:text/html},
	url_Paper = {https://inbs.med.utoronto.ca/wp-content/uploads/2022/01/KOZLOW1.pdf}
}

Downloads: 1

{"_id":"fEDXpsyzRExB7DQ3z","bibbaseid":"kozlowski-abdoumohamed-kim-bell-zagorovsky-mubareka-chan-acolorimetrictesttodifferentiatepatientsinfectedwithinfluenzafromcovid19-2021","author_short":["Kozlowski, H. N.","Abdou Mohamed, M. A.","Kim, J.","Bell, N. G.","Zagorovsky, K.","Mubareka, S.","Chan, W. C. W."],"bibdata":{"bibtype":"article","type":"article","title":"A Colorimetric Test to Differentiate Patients Infected with Influenza from COVID-19","volume":"2","issn":"2688-4062","url":"https://onlinelibrary.wiley.com/doi/abs/10.1002/sstr.202100034","doi":"10.1002/sstr.202100034","abstract":"Patients infected with SARS-CoV-2 and influenza display similar symptoms, but treatment requirements are different. Clinicians need to accurately distinguish SARS-CoV-2 from influenza to provide appropriate treatment. Here, the authors develope a color-based technique to differentiate between patients infected with SARS-CoV-2 and influenza A using a nucleic acid enzyme-gold nanoparticle (GNP) molecular test requiring minimal equipment. The MNAzyme and GNP probes are designed to be robust to viral mutations. Conserved regions of the viral genomes are targeted, and two MNAzymes are created for each virus. The ability of the system to distinguish between SARS-CoV-2 and influenza A using 79 patient samples is tested. When detecting SARS-CoV-2 positive patients, the clinical sensitivity is 90%, and the specificity is 100%. When detecting influenza A, the clinical sensitivity and specificity are 93% and 100%, respectively. The high clinical performance of the MNAzyme-GNP assay shows that it can be used to help clinicians choose effective treatments.","language":"en","number":"8","urldate":"2021-11-06","journal":"Small Structures","author":[{"propositions":[],"lastnames":["Kozlowski"],"firstnames":["Hannah","N."],"suffixes":[]},{"propositions":[],"lastnames":["Abdou","Mohamed"],"firstnames":["Mohamed","A."],"suffixes":[]},{"propositions":[],"lastnames":["Kim"],"firstnames":["Jisung"],"suffixes":[]},{"propositions":[],"lastnames":["Bell"],"firstnames":["Natalie","G."],"suffixes":[]},{"propositions":[],"lastnames":["Zagorovsky"],"firstnames":["Kyryl"],"suffixes":[]},{"propositions":[],"lastnames":["Mubareka"],"firstnames":["Samira"],"suffixes":[]},{"propositions":[],"lastnames":["Chan"],"firstnames":["Warren","C.","W."],"suffixes":[]}],"year":"2021","note":"_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/sstr.202100034","keywords":"colorimetric, diagnostics, DNAzymes, gold nanoparticles, influenza A, respiratory infections, SARS-CoV-2","pages":"2100034","file":"Full Text PDF:files/1780/Kozlowski et al. - 2021 - A Colorimetric Test to Differentiate Patients Infe.pdf:application/pdf;Snapshot:files/1781/sstr.html:text/html","url_paper":"https://inbs.med.utoronto.ca/wp-content/uploads/2022/01/KOZLOW1.pdf","bibtex":"@article{kozlowski_colorimetric_2021,\n\ttitle = {A {Colorimetric} {Test} to {Differentiate} {Patients} {Infected} with {Influenza} from {COVID}-19},\n\tvolume = {2},\n\tissn = {2688-4062},\n\turl = {https://onlinelibrary.wiley.com/doi/abs/10.1002/sstr.202100034},\n\tdoi = {10.1002/sstr.202100034},\n\tabstract = {Patients infected with SARS-CoV-2 and influenza display similar symptoms, but treatment requirements are different. Clinicians need to accurately distinguish SARS-CoV-2 from influenza to provide appropriate treatment. Here, the authors develope a color-based technique to differentiate between patients infected with SARS-CoV-2 and influenza A using a nucleic acid enzyme-gold nanoparticle (GNP) molecular test requiring minimal equipment. The MNAzyme and GNP probes are designed to be robust to viral mutations. Conserved regions of the viral genomes are targeted, and two MNAzymes are created for each virus. The ability of the system to distinguish between SARS-CoV-2 and influenza A using 79 patient samples is tested. When detecting SARS-CoV-2 positive patients, the clinical sensitivity is 90\\%, and the specificity is 100\\%. When detecting influenza A, the clinical sensitivity and specificity are 93\\% and 100\\%, respectively. The high clinical performance of the MNAzyme-GNP assay shows that it can be used to help clinicians choose effective treatments.},\n\tlanguage = {en},\n\tnumber = {8},\n\turldate = {2021-11-06},\n\tjournal = {Small Structures},\n\tauthor = {Kozlowski, Hannah N. and Abdou Mohamed, Mohamed A. and Kim, Jisung and Bell, Natalie G. and Zagorovsky, Kyryl and Mubareka, Samira and Chan, Warren C. W.},\n\tyear = {2021},\n\tnote = {\\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/sstr.202100034},\n\tkeywords = {colorimetric, diagnostics, DNAzymes, gold nanoparticles, influenza A, respiratory infections, SARS-CoV-2},\n\tpages = {2100034},\n\tfile = {Full Text PDF:files/1780/Kozlowski et al. - 2021 - A Colorimetric Test to Differentiate Patients Infe.pdf:application/pdf;Snapshot:files/1781/sstr.html:text/html},\n\turl_Paper = {https://inbs.med.utoronto.ca/wp-content/uploads/2022/01/KOZLOW1.pdf}\n}\n\n","author_short":["Kozlowski, H. N.","Abdou Mohamed, M. A.","Kim, J.","Bell, N. G.","Zagorovsky, K.","Mubareka, S.","Chan, W. C. W."],"key":"kozlowski_colorimetric_2021","id":"kozlowski_colorimetric_2021","bibbaseid":"kozlowski-abdoumohamed-kim-bell-zagorovsky-mubareka-chan-acolorimetrictesttodifferentiatepatientsinfectedwithinfluenzafromcovid19-2021","role":"author","urls":{"Paper":"https://onlinelibrary.wiley.com/doi/abs/10.1002/sstr.202100034"," paper":"https://inbs.med.utoronto.ca/wp-content/uploads/2022/01/KOZLOW1.pdf"},"keyword":["colorimetric","diagnostics","DNAzymes","gold nanoparticles","influenza A","respiratory infections","SARS-CoV-2"],"metadata":{"authorlinks":{}},"downloads":1,"html":""},"bibtype":"article","biburl":"https://inbslab.com//wp-content/uploads/2024/03/Chan-2024_03-14.txt","dataSources":["zb3p4i4Fd9wXynbkF","pF7M3AvRzd8m3Nc5t","BqtRhZTYdfYNLhWzp","sBWiDMMhfDHZnN93b","zkBeHFgTXc62hytzj","s3xwaPmQ7EjjEcMSb","5npqWkz6DHBZLyn3J","yc5dXnBwovT8YvCrt","nLduyq7S9B96QB8B5","JiWrSgLBTKbDLqiYi"],"keywords":["colorimetric","diagnostics","dnazymes","gold nanoparticles","influenza a","respiratory infections","sars-cov-2"],"search_terms":["colorimetric","test","differentiate","patients","infected","influenza","covid","kozlowski","abdou mohamed","kim","bell","zagorovsky","mubareka","chan"],"title":"A Colorimetric Test to Differentiate Patients Infected with Influenza from COVID-19","year":2021,"downloads":1}